This reference contains FDA-approved drug label information, including warnings and precautions, drug interactions, and full-color images of some drugs. Every label includes information on dosages, side effects, and safety information, such as contraindications, pregnancy ratings, and interactions with other drugs, food, or alcohol.

This book predicts the decline of today's professions and introduces the people and systems that will replace them. In an internet-enhanced society, according to Richard Susskind and Daniel Susskind, we will neither need nor want doctors, teachers, accountants, architects, the clergy, consultants, lawyers, and many others, to work as they did in the 20th century. The Future of the Professions explains how increasingly capable technologies - from telepresence to artificial intelligence - will place the 'practical expertise' of the finest specialists at the fingertips of everyone, often at no or low cost and without face-to-face interaction. The authors challenge the 'grand bargain' - the arrangement that grants various monopolies to today's professionals. They argue that our current professions are antiquated, opaque and no longer affordable, and that the expertise of their best is enjoyed only by a few. In their place, they propose five new models for producing and distributing expertise in society. The book raises profound policy issues, not least about employment (they envisage a new generation of 'open-collared workers') and about control over online expertise (they warn of new 'gatekeepers') - in an era when machines become more capable than human beings at most tasks. With a new preface exploring recent critical developments, this updated edition builds on the authors' groundbreaking research into more than a dozen professions. Illustrated with numerous examples from each, this is the first book to assess and question the relevance of the professions in the 21st century.

This book describes seven areas in the field of biotechnology operations as practiced by biopharmaceutical firms and nonprofit institutions. Revisions focus upon changes that have occurred in several areas over the past six years, with emphasis on regulatory, biomanufacturing, clinical and technical information, along with processes and guidlines that have added to the discipline. Examples are increased for new technical fields such as cell and tissue engineering. Further, illustrations or figures are added to each chapter to emphasize particular points.

• Describes regulatory testing requirements for all the major classes of marketed products • Explains how to prepare required documents for mandated safety testing of product • Features new chapters addressing Safety Data Sheet Preparation and Regulatory Requirements for GMOs • Covers Safety Data Sheet Preparation, which has replaced the Material Safety Data Sheet system

Advances in Treatment of Bipolar Disorders provides clinicians with a well-written and timely guide to the most recent advances in the treatment of patients with this complex disorder. Staying abreast of new research developments and treatment options presents a daunting challenge, but the editor and coauthors have compiled the most important evidence-based findings from controlled studies and U.S. Food and Drug Administration approved indications, facilitating integration of these findings into clinical practice. This volume strives to provide clinicians with the necessary information to enable them to balance the likelihood of benefit (using “number needed to treat” analyses) versus harm (using “number needed to harm” analyses) in order to provide individualized, state-of-the-art, evidence-based care. The most current research findings are complemented by the authors’ extensive personal clinical experiences, resulting in a volume that reflects the most up-to-date thinking about the diagnosis and management of bipolar disorder. Advances in Treatment of Bipolar Disorders belongs in every mental health clinician’s library.

The American Psychiatric Association Publishing Textbook of Psychopharmacology is an indispensable and comprehensive resource for clinicians and trainees who prescribe psychotropic medications. Updated to reflect the new DSM-5 classification, this revised Fifth Edition maintains the user-friendly structure of its predecessors while offering in-depth coverage of the latest research in pharmacological principles, classes of drugs, and psychiatric disorders. Introductory chapters provide a theoretical grounding in clinical applications, with topics ranging from neurotransmitters to brain imaging in psychopharmacology. The bulk of the book is devoted to various classes of drugs, including antidepressants, anxiolytics, antipsychotics, mood stabilizers, and other agents, with each class divided into chapters on specific drugs -- either new or revised to include the latest findings and trends. Finally, the section on psychopharmacological treatment addresses evidence-based principles of clinical care for the full spectrum of mental disorders and conditions -- from depression to chronic pain -- as well as for specific populations and circumstances -- from children and adolescents to psychiatric emergencies -- offering information on topics such as medication selection, combination and maintenance dosing regimens, monitoring and management of side effects, and strategies for optimizing treatment response. The book's beneficial features are many: The section on principles of pharmacology has been revised and reorganized to incorporate recent discoveries from the fields of neurobiology, genetics, brain imaging, and epidemiology. History and discovery, structure--activity relationships, pharmacological profiles, pharmacokinetics and disposition, mechanisms of action, indications and efficacy, side effects and toxicology, and drug--drug interactions are addressed for each agent. This consistent structure places the desired information at the clinician's fingertips and facilitates study for trainees. Coverage of drugs approved since the last edition is thorough, encompassing new antidepressants (e.g., vortioxetine), new antipsychotics (e.g., cariprazine), and agents on the clinical horizon (e.g., ketamine). More than 180 tables and graphs present critically important data in an accessible way. A work of uncommon scientific rigor and clinical utility, The American Psychiatric Association Publishing Textbook of Psychopharmacology provides state-of-the-art information on both the principles and the practice of psychopharmacological treatment of psychiatric disorders.